Bio-Techne Corporation (NasdaqGS:TECH) is looking for M&A. During the company?s earnings conference call for the second quarter of fiscal year 2024, James Hippel, Chief Financial Officer said that ?We finished the quarter with 160.1 million average diluted shares outstanding. Our balance sheet finished Second Quarter in a strong position with $135.6 million in cash, and our total leverage stood below 1x EBITDA. Going forward, M&A remains a top priority for capital allocation?.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
79.63 USD | +3.35% | +5.33% | +3.20% |
May. 06 | Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating | MT |
May. 02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.20% | 12.14B | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
-2.67% | 12.08B | |
+30.23% | 11.98B | |
+20.99% | 11.58B |
- Stock Market
- Equities
- TECH Stock
- News Bio-Techne Corporation
- Bio-Techne Seeks M&A